Nexomic builds a large-scale patient multi-omic data foundation enhanced by a proprietary, tumor-agnostic AI foundation model called DeepOmic®. The platform decodes the hidden biology driving treatment response, resistance, and disease evolution to support drug target discovery and de-risk clinical development. DeepOmic® is a 4-billion-parameter model that generates 8,000-dimensional biological embeddings from over 100 million molecular features per patient.
- Artificial Intelligence
- Biotechnology
- Drug Discovery & Therapeutics
- Healthcare Technology
- Software Only
Funding
Funding not disclosed
Founders
Product
Problem
Cancer treatment response and resistance are driven by complex, hidden biological mechanisms that standard genomic analysis fails to capture. Drug developers and clinicians lack integrated, multi-omic views of real-patient tumor biology, leading to failed clinical trials, ineffective therapies, and delayed precision oncology advances.
Solution
Nexomic has built a large-scale patient multi-omic data foundation that reflects the diversity and complexity of tumor biology, enhanced by proprietary computational deep profiling approaches and a state-of-the-art, tumor-agnostic AI foundation model called DeepOmic®. The platform integrates over five layers of multi-omics data with clinically linked outcomes from more than 30 countries, including rare subtypes, to create a unified AI representation of disease biology across omics, patients, and cancer types. DeepOmic® generates high-dimensional biological embeddings that capture complex multi-omic disease signals, enabling researchers to screen molecular landscapes for new drug targets and decode latent biology driving heterogeneity and resistance. The company offers solutions for drug target discovery in resistant patient populations and for sponsors seeking to de-risk drug development by grounding clinical design in real-patient multi-omic biology.
Target Audience
Primary customers are pharmaceutical and biotech sponsors in drug discovery and clinical development, as well as academic and clinical research institutions seeking to identify novel drug targets and understand treatment resistance mechanisms.
Features
- DeepOmic® foundation model with 4 billion parameters, purpose-built to decode cancer biology
- 8,000-dimensional biological embeddings capturing complex multi-omic disease signals
- Data foundation spanning 5+ layers of multi-omics data with clinically linked outcomes from 30+ countries
- Over 1 million harmonized features per patient and 100 million+ molecular features modeled
- Tumor-agnostic AI architecture validated across diverse patient datasets for robust, clinically relevant insights
- OMEGA collaborative research initiative connecting clinical outcomes, patient specimens, and multi-omic data to advance oncology discovery